Loading...
Please wait, while we are loading the content...
Similar Documents
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
| Content Provider | Scilit |
|---|---|
| Author | Greenberg, Peter L. Tuechler, Heinz Schanz, Julie Sanz, Guillermo Garcia-Manero, Guillermo Solé, Francesc Bennett, John M. Bowen, David Fenaux, Pierre Dreyfus, Francois Kantarjian, Hagop Kuendgen, Andrea Levis, Alessandro Malcovati, Luca Cazzola, Mario Cermak, Jaroslav Fonatsch, Christa Beau, Michelle M. Le Slovak, Marilyn L. Krieger, Otto Luebbert, Michael Maciejewski, Jaroslaw Magalhaes, Silvia M. M. Miyazaki, Yasushi Pfeilstöcker, Michael Sekeres, Mikkael Sperr, Wolfgang R. Stauder, Reinhard Tauro, Sudhir Valent, Peter Vallespi, Teresa Loosdrecht, Arjan A. Van De Germing, Ulrich Haase, Detlef |
| Copyright Year | 2012 |
| Description | The International Prognostic Scoring Sytem (IPSS) is an important standard for ssessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS patient databases from international institutions were coalesced to assemble a much larger combined database (Revised-IPSS [IPSS-R], n = 7012, IPSS, n = 816) for analysis. Multiple statistically weighted clinical features were used to generate a prognostic categorization model. Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the new system. Novel components of the current analysis included: 5 rather than 3 cytogenetic prognostic subgroups with specific and new classifications of a number of less common cytogenetic subsets, splitting the low marrow blast percentage value, and depth of cytopenias. This model defined 5 rather than the 4 major prognostic categories that are present in the IPSS. Patient age, performance status, serum ferritin, and lactate dehydrogenase were significant additive features for survival but not for acute myeloid leukemia transformation. This system comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS. As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425443/pdf |
| Ending Page | 2465 |
| Page Count | 12 |
| Starting Page | 2454 |
| DOI | 10.1182/blood-2012-03-420489 |
| Journal | Blood |
| Issue Number | 12 |
| Volume Number | 120 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2012-09-20 |
| Access Restriction | Open |
| Subject Keyword | Cell Tissue Engineering Survival Bone Marrow Model Prognosis Adult Prognostic System Mds Cytogenetic Ipss Journal: Blood (Vol- 121, Issue- 12) |
| Content Type | Text |
| Resource Type | Article |
